金沙检测线路js333-金沙检测线路js333

Becoming a global leader in structural heart disease

Becoming a global leader in structural heart disease

Company Overview

---------

Founded in 2009, Venus Medtech is located in Hangzhou National High-Tech Industrial Development Zone (Binjiang) and is committed to the development and industrialization of transcatheter therapy products for structural heart disease. On December 10th, 2019, the company was listed on the main board of the Hong Kong Stock Exchange (SEHK) with stock code 02500.

The company's all series of “China Intelligently Manufactured " valves has been introduced to more than 30 countries and regions worldwide, including Asia, Europe, South America and North America, and has established a comprehensive heart valve line. By providing patients with a full range of TAVR solutions and accessory products, the company is committed to addressing the huge unmet demand of TPVR, TMVR and TTVR in China and around the world.

Aortic Valve Disease-Solutions Pulmonic Valve Disease-Solutions Mitral/Tricuspid Valve Disease-Solutions Hypertension Diseases-Solutions Hypertrophic Cardiomyopathy-Solutions